Mark Iwicki's Planned Sale of Kala Bio, Inc. Securities

Mark Iwicki, a director of Kala Bio, Inc., has filed a notice of intent to sell 154,894 shares of common stock acquired through the vesting of Restricted Stock and Performance Shares. The Restricted Stock was acquired on 06/25/2021, and the Performance Shares were acquired on 10/26/2021. The planned sale is scheduled for 10/23/2025, with an aggregate market value of $125,185.33. The securities are held on the NASDAQ exchange, and the sale will be facilitated by Morgan Stanley Smith Barney LLC Executive Financial Services. No securities were sold in the past three months.